PMID: 9443523Jan 1, 1997Paper

Changes in plasma prolactin during SSRI treatment: evidence for a delayed increase in 5-HT neurotransmission

Journal of Psychopharmacology
P J Cowen, P A Sargent

Abstract

We studied the effect of the selective serotonin reuptake inhibitor (SSRI), paroxetine, on basal plasma prolactin concentrations in 11 healthy subjects. Subjects were tested before paroxetine, and after 1 and 3 weeks of treatment (20 mg daily). On each test occasion prolactin levels were sampled before and following administration of a placebo capsule, for a total of 4 h. After 3 weeks paroxetine treatment plasma prolactin levels were significantly higher than those seen either pre-treatment or after 1 week of treatment. In contrast, 1 week of paroxetine treatment did not significantly increase prolactin concentrations over pre-treatment values. Plasma concentrations of paroxetine did not differ between 1 and 3 weeks of treatment. The secretion of plasma prolactin is, in part, under the tonic regulation of serotonergic pathways and the present results therefore support animal experimental data suggesting that SSRIs produce a delayed increase in some aspects of brain serotonin neurotransmission.

References

May 1, 1977·The Journal of Clinical Endocrinology and Metabolism·G LaakmannO Benkert
Jan 1, 1991·Annual Review of Pharmacology and Toxicology·L D Van de Kar
Mar 1, 1989·The Journal of Clinical Endocrinology and Metabolism·R N GoldenW Z Potter
Apr 1, 1995·Psychopharmacology·S B Park, P J Cowen
Jul 1, 1994·Trends in Pharmacological Sciences·P Blier, C de Montigny
Apr 1, 1996·Psychopharmacology·Y K WingP J Cowen
Apr 1, 1996·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·E SeifritzE Holsboer-Trachsler
Aug 1, 1997·Psychopharmacology·P SargentP J Cowen
Jan 1, 1991·Journal of Psychopharmacology·J F Deakin, F G Graeff

❮ Previous
Next ❯

Citations

Dec 3, 2005·Breast Cancer Research and Treatment·Chloe ChienJanet R Daling
Jul 20, 2007·Breast Cancer Research and Treatment·Patricia F CooganLynn Rosenberg
Nov 10, 2012·Breast Cancer Research and Treatment·Chun-Sick EomKyung-Hwan Cho
Feb 5, 2008·Journal of Mammary Gland Biology and Neoplasia·Shelley S Tworoger, Susan E Hankinson
Apr 12, 2008·Pituitary·Mark E Molitch
Sep 30, 1999·Life Sciences·D K Raap, L D Van de Kar
Feb 12, 2002·Neuroscience and Biobehavioral Reviews·Tillmann H C KrügerMichael S Exton
Jan 15, 2005·Journal of Child and Adolescent Psychopharmacology·Ema SaitoVivian Kafantaris
May 9, 2009·Psychological Science·Mitchell E BermanEmil F Coccaro
Jun 18, 2009·European Journal of Applied Physiology·Bart RoelandsRomain Meeusen
Nov 26, 2010·The Journal of Sexual Medicine·Angel-Luis MontejoMichael J Detke
Sep 8, 2009·Progress in Neuro-psychopharmacology & Biological Psychiatry·Johanna HilliKari Laine
May 12, 2009·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Tamar WohlfarthChristine Gispen-de Wied
Aug 12, 2005·Mayo Clinic Proceedings·Mark E Molitch
Dec 3, 2005·Child and Adolescent Psychiatric Clinics of North America·Amy L Becker, C Neill Epperson
Feb 20, 2009·Pharmacoepidemiology and Drug Safety·Karen J WernliPolly A Newcomb
Jan 22, 2011·Pharmacoepidemiology and Drug Safety·Karen J WernliPolly A Newcomb
Sep 3, 2011·Journal of Applied Toxicology : JAT·Adam Hargreaves, Johannes Harleman
Jun 4, 2010·Human Psychopharmacology·Subramoniam MadhusoodananCarolina Jimenez
Mar 31, 2005·Cancer Letters·Reina HaqueDiana B Petitti
Aug 15, 2015·Psycho-oncology·Vincent Chin-Hung ChenCharles Tzu-Chi Lee
May 12, 2016·Cancer Causes & Control : CCC·Katherine W ReevesSusan E Hankinson
Jan 23, 2010·The Journal of Sexual Medicine·Margaret E WiermanJan L Shifren
Oct 3, 2006·Expert Review of Neurotherapeutics·Patricia F Coogan
Mar 5, 2004·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Ana B F Emiliano, Julie L Fudge
Jan 21, 2018·Breast Cancer Research : BCR·John BusbyChris R Cardwell
Dec 3, 2013·Therapeutic Advances in Psychopharmacology·Somnath MondalSantanu Kumar Tripathi
Apr 22, 2005·British Journal of Clinical Pharmacology·G J H DumontUNKNOWN Biomarker Working Group of the German Association for Applied Human Pharmacology
May 6, 2004·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Haitham S NadeemPhilip J Cowen
Mar 9, 2006·British Journal of Cancer·D Fulton-KehoeN S Weiss
Jul 21, 2007·Neuropsychobiology·Mattie TopsJakob Korf
Feb 6, 1999·Journal of Clinical Psychopharmacology·R C RosenM Menza
Dec 6, 2000·Journal of Clinical Psychopharmacology·A Aberg-WistedtA C Akerblad
Nov 18, 2020·Trends in Pharmacological Sciences·Abigail C Cornwell, Michael E Feigin
Jan 21, 2006·The Journal of Sexual Medicine·Rossella NappiIrwin Goldstein

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.